China National Medicines (SHSE:600511) Research & Development: ¥68 Mil (TTM As of Mar. 2026)


SHSE:600511 China National Medicines Corp Ltd SHSE:600511
86 GF Score
Price ¥26.94
GF Value ¥32.74
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is China National Medicines Research & Development?

China National Medicines SHSE:600511 +1.62% 86 Research & Development is ¥68 Mil as of Mar. 2026. GuruFocus rates SHSE:600511 with a GF Score™ of 86/100 and a GF Value™ of ¥32.74 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. China National Medicines's Research & Development for the three months ended in Mar. 2026 was ¥13 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥68 Mil.

China National Medicines  (SHSE:600511) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

China National Medicines Research & Development Related Terms

China National Medicines Research & Development Historical Data

* Premium members only.

The historical data trend for China National Medicines's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China National Medicines Research & Development Chart

China National Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.75 67.00 71.20 73.71 69.31

China National Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.82 14.20 15.58 25.71 12.77
SHSE:600511
86GF Score
China National Medicines Corp Ltd SHSE:600511
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China National Medicines Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥68 Mil mean?
China National Medicines (SHSE:600511) has a Research & Development of ¥68 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on China National Medicines and its competitors.
Is China National Medicines' Research & Development too high?
China National Medicines' current Research & Development is ¥68 Mil. Overall, China National Medicines has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Research & Development compare to MCK and CAH?
China National Medicines' Research & Development of ¥68 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on China National Medicines and its competitors. China National Medicines's current Research & Development is ¥68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.74, compared to a current price of ¥26.94 — trading 17.7% below its estimated fair value. The current Research & Development is ¥68 Mil. China National Medicines' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Research & Development is ¥68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China National Medicines (SHSE:600511) Overvalued in 2026?

Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued. The current stock price of ¥26.94 is trading 17.7% below its estimated GF Value™ of ¥32.74. GuruFocus considers China National Medicines to be Modestly Undervalued.

Key valuation signals for SHSE:600511:

  • Research & Development: ¥68 Mil
  • GF Value™: ¥32.74 vs. price of ¥26.94 (17.7% below fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China National Medicines Business Description

Address No. 8, Xibinhe Road, Floor 6-9, West Tower, 7th Floor, Yongdingmen, Dongcheng District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
86GF Score

Get the complete analysis for SHSE:600511

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.94
Price
¥32.74
GF Value